Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patients
Ángela Santonja(University of Cambridge), Emilio Alba(Hospital Clínico Universitario Virgen de la Victoria), Arthur Jeiranian(Hospital Costa del Sol), Irene Zarcos(Hospital Costa del Sol), Martina Álvarez(Hospital Costa del Sol), Luís Vicioso(Hospital Costa del Sol), Carla Sousa(Hospital Costa del Sol), Aileen I. Fernandez(Yale University), Pedro Sánchez‐Rovira(Complejo Hospitalario de Jaén), Eduardo Villar(Hospital Costa del Sol), Carl Schaper(Hospital Costa del Sol), Naeem Dowidar(Hospital Costa del Sol), César E. Ramírez(Hospital Costa del Sol), Begoña Jiménez-Rodríguez(Hospital Costa del Sol), Wesley Buckingham(Hospital Costa del Sol), Nuria Ribelles(Instituto de Investigación Biomédica de Málaga), Aleix Prat(Hospital Clínic de Barcelona), Sean Ferree(Hospital Costa del Sol), Vanessa de Luque(Hospital Costa del Sol), C González-Hermoso(Hospital Costa del Sol)
Cited by 1
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k